Most Recent
An environmental group is challenging the approval of an extension for Whitehaven's Narrabi coal mine, arguing the NSW Independent Planning Commission failed to consider the project's impact on climate change.
Failed neobank Volt is facing an investor class action investigation over representations made in a series of funding rounds that raised $219 million before announcing last week that it would shut its doors.
Crown Resorts could face another record fine after Victoria's gambling regulator launched fresh disciplinary proceedings seeking information about the casino's alleged failure to properly supervise problem gamblers.
A man who says he was falsely accused by a Seven journalist of spitting at an alleged rape victim of rugby league footballer Jarryd Hayne must hand over key CCTV footage he claims vindicates him in his defamation suit against Seven.
Twitter personality Alan Davison, who runs the account Stock Swami, has admitted he misled lawyers for mining investor Tolga Kumova and deliberately failed to obey court orders for discovery in cross-examination during a defamation trial.
The lead applicant in an unsuccessful class action over the Carwoola bushfire has avoided indemnity costs sought by insurer CGU and has won a 40 per cent reduction in the amount of legal costs it will have to cover for the defendant.
A judge has told Forum Finance director Vince Tesoriero to “revisit” evidence about his true financial position if he wants to win the release of $1.25 million to pay for his defence in Westpac’s fraud case against him, amid concerns about whether he has made full disclosure to the court.
Three AGL Energy subsidiaries have been ordered to pay $3.5 million in penalties for breaches of energy rules that led to a statewide blackout in South Australia.
Channel Seven has asked the Federal Court to terminate a Test cricket and Big Bash League broadcast agreement with Cricket Australia due to alleged contract breaches.
Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi's patent for a biosimilar of blockbuster arthritis drug Humira.